Document Detail

Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
MedLine Citation:
PMID:  16480743     Owner:  NLM     Status:  MEDLINE    
There is an unmet need to develop specific biomarkers for multiple sclerosis (MS) to aid in the diagnosis, improve the management of patients and the monitoring of the effectiveness of treatment. We have screened serum from patients with relapsing-remitting MS (RRMS, n = 107) against a library of glycans on a glycan chip, and have found significantly higher levels of IgM anti-Glc(alpha1,4)Glc(alpha) antibodies (anti-Galpha4Galpha antibodies) than in patients suffering from other neurological diseases (OND, n = 50, p < 0.0001), and other autoimmune diseases (OAD, n = 27, p = 0.02). No significant differences were found relative to patients having primary progressive MS (n = 16). No significant differences were detected between the levels of IgM anti-Galpha4Galpha antibodies in sera from patients with RRMS in relapsing versus remitting state, and in patients treated with immunotherapy versus untreated patients. To test whether the highly significant difference in the levels of IgM anti-Galpha4Galpha between RRMS and OND group is due to general increase in IgM levels, we have measured total serum IgM in a subgroup of 62 MS and 48 OND patients. Although the total IgM was significantly lower in the OND than the RRMS group (p = 0.0007), analysis of covariance (ANCOVA) reveled no statistically significant relationship to the covariate (total IgM). Furthermore, following normalizing the values to total IgM the difference in the levels of IgM anti-Galpha4Galpha between the MS and OND groups was found highly significant (p < < 0.0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management.
Mikael Schwarz; Larissa Spector; Monica Gortler; Oori Weisshaus; Lea Glass-Marmor; Arnon Karni; Nir Dotan; Ariel Miller
Related Documents :
19831123 - Gait apraxia in multiple sclerosis.
72793 - Serological response of multiple sclerosis patients and controls to 6/94-parainfluenza ...
20876673 - Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.
Publication Detail:
Type:  Journal Article     Date:  2006-02-09
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  244     ISSN:  0022-510X     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-26     Completed Date:  2006-07-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  59-68     Citation Subset:  IM    
Glycominds Ltd, Lod 71291, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantibodies / blood*,  immunology*
Biological Markers / blood
False Positive Reactions
Fluorescent Antibody Technique
Immunoglobulin M / blood*,  immunology*
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / blood*,  diagnosis,  immunology*
Oligosaccharides / immunology
Polysaccharides / immunology*
Predictive Value of Tests
Reg. No./Substance:
0/Autoantibodies; 0/Biological Markers; 0/Immunoglobulin M; 0/Oligosaccharides; 0/Polysaccharides; 35175-16-7/glucose tetrasaccharide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences in cerebral activation patterns in idiopathic inflammatory demyelination using the paced...
Next Document:  The presence of high concentrations of free D-amino acids in human saliva.